VIVUS (VVUS) : 5 analysts are covering VIVUS (VVUS) and their average rating on the stock is 2.8, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. 1 more analyst has given the stock a Sell recommendation. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
VIVUS (VVUS) : The highest level VIVUS (VVUS) is projected to reach is $3 for the short term and the lowest estimate is at $1. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $1.9 and the possibility the share price can swing is $1.27.
VIVUS (NASDAQ:VVUS): The stock opened at $1.17 on Wednesday but the bulls could not build on the opening and the stock topped out at $1.19 for the day. The stock traded down to $1.14 during the day, due to lack of any buying support eventually closed down at $1.14 with a loss of -2.56% for the day. The stock had closed at $1.17 on the previous day. The total traded volume was 317,285 shares.
The company shares have dropped -44.55% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $2.35 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $1.18 and the 200 Day Moving Average price is recorded at $1.22.
VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42,000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. As of September 18, 2014, the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.